Cardiometabolic Phenotype in HFpEF: Insights from Murine Models

Cardiometabolic Phenotype in HFpEF: Insights from Murine Models

Heart failure with preserved ejection fraction (HFpEF) remains a significant challenge in modern healthcare. It accounts for the majority of heart failure cases and their number worldwide is steadily increasing. With its high prevalence and substantial clinical impact, therapeutic strategies for HFp...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ekaterina Ogurtsova, Tatiana Arefieva, Anastasiia Filatova, Natalya Radyukhina, Artem Ovchinnikov
Format:	Article
Language:	English
Published:	MDPI AG 2025-03-01
Series:	Biomedicines
Subjects:	heart failure with preserved ejection murine models myocardial fibrosis diastolic dysfunction cardiometabolic HFpEF
Online Access:	https://www.mdpi.com/2227-9059/13/3/744
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Circulating mediators linking cardiometabolic diseases to HFpEF: a mediation Mendelian randomization analysis
by: Mingzhi Lin, et al.
Published: (2025-05-01)

The Possible Role of Rosuvastatin Therapy in HFpEF Patients—A Preliminary Report
by: Tomasz Urbanowicz, et al.
Published: (2024-11-01)

Microvascular dysfunction across organs in heart failure with preserved ejection fraction: the PROSE-HFpEF case-control study
by: Jerremy Weerts, et al.
Published: (2025-07-01)

Metabolic rewiring and inter-organ crosstalk in diabetic HFpEF
by: Lingyun Luo, et al.
Published: (2025-04-01)

Gender-Specific Differences in Diastolic Dysfunction and HFpEF: Pathophysiology, Diagnosis, and Therapeutic Strategies
by: Francesca Coppi, et al.
Published: (2025-06-01)

The gut microbiota-inflammation-HFpEF axis: deciphering the role of gut microbiota dysregulation in the pathogenesis and management of HFpEF
by: Shenghua Zhou, et al.
Published: (2025-03-01)

Targeting atrial fibrillation in HFpEF: the emerging role of pulsed field ablation
by: A. S. Parwani, et al.
Published: (2025-07-01)

Identification of noval diagnostic biomarker for HFpEF based on proteomics and machine learning
by: Muyashaer Abudurexiti, et al.
Published: (2025-04-01)

Sex‐related pathophysiological mechanisms may be present before symptoms of HFpEF develop
by: B. Wong, et al.
Published: (2025-06-01)

Sex differences in the association between nutritional status and in‐hospital mortality in HFpEF patients
by: Michał Czapla, et al.
Published: (2025-08-01)

Specific targeting of adipose tissue metabolism is superior to caloric restriction in treating obesity-related HFpEF
by: Simon Sedej, et al.
Published: (2025-07-01)

Mechanism-based myofilament manipulation to treat diastolic dysfunction in HFpEF
by: Katherine L. Dominic, et al.
Published: (2024-12-01)

Schaftoside improves HFpEF through regulation the autophagy-lysosome pathway by allosterically targeting CaMKII-δ
by: Haiying Zhang, et al.
Published: (2024-12-01)

Hepatocyte growth factor and B-type natriuretic peptide as independent predictors of mortality in HFpEF patients
by: Hou-liang Chen, et al.
Published: (2025-02-01)

Cardiovascular Outcomes of Semaglutide vs Dulaglutide in Nonobese Type II Diabetes Patients With HFpEF
by: Patrick A. Kwaah, MBChB, et al.
Published: (2025-07-01)

Prognostic significance of FT3 levels in hypertrophic cardiomyopathy patients with HFpEF
by: Zhen-Yu Yang, et al.
Published: (2025-08-01)

Type 2 diabetes worsens the outcome of ischemia/reperfusion in female STEMI patients and female db/db mice with HFpEF cardiometabolic phenotype
by: Ivana Iveljic, et al.
Published: (2025-06-01)

The landscape of novel antidiabetic drugs in diabetic HFpEF: relevant mechanisms and clinical implications
by: Xiangling Duan, et al.
Published: (2025-04-01)

Prognosis of early‐stage HFpEF in the community‐dwelling elderly: The Northern Shanghai Study
by: Weilun Meng, et al.
Published: (2025-02-01)

Impact of SGLT2 inhibitors on myocardial fibrosis in diabetic HFpEF: a longitudinal study
by: Arif Albulushi, et al.
Published: (2025-07-01)

Ventricular interdependent phenotype of mixed Cpc‐pulmonary hypertension and HFpEF with normal left atrium: Impact on CPET metrics and clinical outcomes
by: Giovanna Zampierollo‐Jaramillo, et al.
Published: (2024-10-01)

MyoMed205 Counteracts Titin Hyperphosphorylation and the Expression of Contraction‐Regulating Proteins in a Rat Model of HFpEF
by: Beatrice Vahle, et al.
Published: (2025-06-01)

Cardiometabolic heart failure with preserved ejection fraction: from molecular signatures to personalized treatment
by: Era Gorica, et al.
Published: (2025-07-01)

Atrial dysfunction: a contrast-free marker for HFpEF in obese diabetics—insights from comprehensive CMR and serum biomarker analyses
by: Rebecca Elisabeth Beyer, et al.
Published: (2025-06-01)

Impact of severe obesity on exercise performance in heart failure with preserved ejection fraction
by: Satyam Sarma, et al.
Published: (2020-11-01)

Relation of left atrial overload indices with prognostic endpoints in heart failure and preserved ejection fraction
by: Shiro Hoshida, et al.
Published: (2022-06-01)

EVOLUTION‐HF DEallEF: A non‐interventional study of patients with heart failure initiated on dapagliflozin: study design
by: Matthias Paul, et al.
Published: (2025-08-01)

Sodium Glucose Transporter 2 Inhibitor Protects Against Heart Failure With Preserved Ejection Fraction: Preclinical “2‐Hit” Model Reveals Autophagy Enhancement Via AMP‐Activated Protein Kinase/Mammalian Target of Rapamycin Complex 1 Pathway
by: Xinyu Hu, et al.
Published: (2025-08-01)

Mural cell dysfunction contributes to diastolic heart failure by promoting endothelial dysfunction and vessel remodelling
by: Mandy O. J. Grootaert, et al.
Published: (2025-02-01)

Targeted Overexpression of Mitochondrial ALDH2 in Coronary Endothelial Cells Mitigates HFpEF in a Diabetic Mouse Model
by: Guodong Pan, et al.
Published: (2025-07-01)

Single nuclei RNA-sequencing unveils alveolar macrophages as drivers of endothelial damage in obese HFpEF-related pulmonary hypertension
by: Era Gorica, et al.
Published: (2025-07-01)

Clinical profile of heart failure in geriatric patients in a tertiary cardiac hospital of Bangladesh
by: Mahbuba Yesmin, et al.
Published: (2025-06-01)

Hospitalized patients and stimulant use-associated heart failure: importance of ejection fraction and related risk factors
by: Akshat Agrawal, et al.
Published: (2025-07-01)

Differential Effects of Landiolol in Patients with Atrial Fibrillation and Atrial Tachycardia
by: Kengo Ayabe, et al.
Published: (2024-10-01)

Small Heart Size and Premature Death in 366,484 Individuals With Normal Ejection Fraction
by: Stephanie J. Rowe, BBiomed, MD, et al.
Published: (2025-01-01)

Impact of Voluntary Exercise on Systemic Inflammation in a 2‐Hit Model of Heart Failure With Preserved Ejection Fraction
by: Heather Quiriarte, et al.
Published: (2025-02-01)

Cardiopulmonary exercise testing as a prognosis‐assessing tool in heart failure with preserved ejection fraction
by: C. Rozados daConceicao, et al.
Published: (2025-06-01)

Exploring the Noninvasive Evaluation of the Pulmonary Pressure–Flow Relationship During Exercise
by: Mads J. Andersen, et al.
Published: (2024-08-01)

Left Atrial Strain in Patients with Chronic Heart Failure with Preserved Ejection Fraction: A Narrative Review
by: Dana Emilia Man, et al.
Published: (2025-02-01)

Investigating the effect of SGLT2 inhibitors on cardiovascular related health status in HFmrEF and HFpEF: systematic review and meta analysis
by: Tabitha Kusi-Yeboah, et al.
Published: (2025-07-01)